Paul A. Friedman
Chief Executive Officer at Madrigal Pharmaceuticals Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Madrigal Pharmaceuticals Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Prelude Therapeutics Incorporated June 14, 202494.7%
-
Madrigal Pharmaceuticals Inc. June 15, 202395.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Option exercise | +280 | $15.80 | $4,424 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Option exercise | +24,520 | $15.80 | $387,416 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −280 | $551.24 | $154,347 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −1,480 | $511.98 | $757,730 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −1,094 | $513.11 | $561,342 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −1,345 | $514.68 | $692,245 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −1,996 | $515.81 | $1,029,557 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −766 | $516.84 | $395,899 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −2,450 | $517.86 | $1,268,757 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −1,363 | $518.68 | $706,961 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −846 | $519.88 | $439,818 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −681 | $521.03 | $354,821 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −840 | $521.98 | $438,463 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −970 | $523.00 | $507,310 |
| Jan 9, 2026 | Madrigal Pharmaceuticals Inc. | Open-market sale | −1,199 | $524.10 | $628,396 |
Questions about Paul A. Friedman
What boards is Paul A. Friedman on?
Paul A. Friedman sits on the boards of Madrigal Pharmaceuticals Inc. and Prelude Therapeutics Incorporated.
Has Paul A. Friedman been a CEO?
Yes — Paul A. Friedman was CEO of Madrigal Pharmaceuticals Inc. (Until September 2023).
How long has Paul A. Friedman served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.